Feature|Videos|September 30, 2024
The Regulatory Stance on Oligonucleotide Enantiomers
Author(s)LCGC Editors
The panel dives into the regulatory stance on oligonucleotide enantiomers. The role of batch-to-batch reproducibility, new drug application (NDA) filing, and current guidelines are covered.
Advertisement
Episodes in this series
Regulatory guidelines must be considered when discussing oligonucleotide analysis and enantiomers. The panel reviews the current regulatory stance on this topic and common analytical bottlenecks relative to regulatory compliance.
Advertisement
Advertisement
Advertisement
Trending on LCGC International
1
HILIC vs Reversed-Phase LC for Central Carbon Metabolism Profiling
2
LC-MS/MS Links Vitamin D Levels to Sleep Timing
3
Analytical Procedure Lifecycle Approaches in Accordance With ICH Q14 and ICH Q2(R2): Opportunity Knocks or Just Another Challenge and Headache? (Part 2)
4
Highlights from the HPLC2026 Conference through the Lens of LC Troubleshooting
5